SOPRANO - Stereotactic radiotherapy alone or stereotactic radiotherapy follow by niraparib treatment for ovarian cancer with progressive disease in three or less lesions, or recurrence of 3 or less metastatic lesions that had previously achieved complete response.

Authors
Category Primary study
Registry of TrialsISRCTN registry
Year 2023
This article has no abstract
Epistemonikos ID: 5340eca80e6929096136ea4b4b3d5f4420121bfd
First added on: Jan 17, 2025